Sumitomo Dainippon Pharma and Kyoto University said on April 11 that they will kick off the second-stage of what they call the “DSK Project,” which was launched five years ago to discover innovative drugs, diagnostic tools, and therapeutic methods in…
To read the full story
Related Article
- DSP to Collaborate with Kyoto Univ. in Cancer Field
March 28, 2011
BUSINESS
- Daiichi Targets 3 Trillion Yen Sales by FY2030, Global Top-5 Oncology Spot
May 12, 2026
- Lilly Japan Hits Record Sales as Mounjaro Tops 100 Billion Yen
May 12, 2026
- Ferring Nabs Japan Approval for Bladder Cancer Gene Therapy
May 12, 2026
- Teijin to Offload Legacy Drug Portfolio as It Speeds Up Pivot to Rare Diseases
May 12, 2026
- Keytruda Extends Run as Japan’s Best-Selling Drug in April: Encise
May 12, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





